Intra-Cellular Therapies, Inc.
ITCI
$131.87
-$0.05-0.04%
| Weiss Ratings | ITCI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ITCI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Good | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | ITCI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.15 | |||
| Price History | ITCI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.14% | |||
| 30-Day Total Return | 2.54% | |||
| 60-Day Total Return | 58.44% | |||
| 90-Day Total Return | 54.32% | |||
| Year to Date Total Return | 56.54% | |||
| 1-Year Total Return | 96.21% | |||
| 2-Year Total Return | 135.44% | |||
| 3-Year Total Return | 109.02% | |||
| 5-Year Total Return | 751.87% | |||
| 52-Week High % Change | -0.08% | |||
| 52-Week Low % Change | 105.76% | |||
| Price | ITCI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $131.98 | |||
| 52-Week Low Price | $64.09 | |||
| 52-Week Low Price (Date) | May 20, 2024 | |||
| 52-Week High Price (Date) | Apr 01, 2025 | |||
| Valuation | ITCI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 14.02B | |||
| Enterprise Value | 13.04B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.72 | |||
| Earnings Per Share Growth | -50.32% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 20.55 | |||
| Price/Book (Q) | 12.20 | |||
| Enterprise Value/Revenue (TTM) | 19.15 | |||
| Price | $131.87 | |||
| Enterprise Value/EBITDA (TTM) | -112.19 | |||
| Enterprise Value/EBIT | -111.70 | |||
| Market Cap Category | Large Cap | |||
| Dividends and Shares | ITCI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 106.10M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ITCI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 646 440 9333 | |||
| Address | 135 Route 202/206 Bedminster, NJ 07921 | |||
| Website | www.intracellulartherapies.com | |||
| Country | United States | |||
| Year Founded | 2002 | |||
| Profitability | ITCI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -17.14% | |||
| Profit Margin | -10.96% | |||
| Management Effectiveness | ITCI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -6.96% | |||
| Return on Equity | -- | |||
| Income Statement | ITCI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 680.85M | |||
| Total Revenue (TTM) | 680.85M | |||
| Revenue Per Share | $6.42 | |||
| Gross Profit (TTM) | 387.77M | |||
| EBITDA (TTM) | -116.21M | |||
| EBIT (TTM) | -116.72M | |||
| Net Income (TTM) | -74.68M | |||
| Net Income Avl. to Common (TTM) | -74.68M | |||
| Total Revenue Growth (Q YOY) | 50.81% | |||
| Earnings Growth (Q YOY) | 40.92% | |||
| EPS Diluted (TTM) | -0.72 | |||
| EPS Diluted Growth (Q YOY) | 46.39% | |||
| Balance Sheet | ITCI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.00B | |||
| Cash Per Share (Q) | $9.44 | |||
| Total Current Assets (Q) | 1.31B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 1.15B | |||
| Current Ratio (Q) | 6.356 | |||
| Book Value Per Share (Q) | $10.81 | |||
| Total Assets (Q) | 1.37B | |||
| Total Current Liabilities (Q) | 205.70M | |||
| Total Debt (Q) | 16.98M | |||
| Total Liabilities (Q) | 218.45M | |||
| Total Common Equity (Q) | 1.15B | |||
| Cash Flow | ITCI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -335.15M | |||
| Cash from Financing (TTM) | 567.51M | |||
| Net Change in Cash (TTM) | 159.18M | |||
| Levered Free Cash Flow (TTM) | -63.59M | |||
| Cash from Operations (TTM) | -73.18M | |||
